Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CXCL9 Monoclonal Antibody (49106), FITC
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA523544
Description
In ELISAs, does not cross-react with recombinant mouse (rm) CXCL9, recombinant human CXCL10.
MIG, also known as CXCL9, is a T-cell chemoattractant inducible by gamma interferon that is a member of the CXC chemokine family of cytokines.This gene is mapped to 4q21. It is noted that, although the best-described activities of the chemokines are as chemotactic factors, chemokines also have an effect on T-cell activation, angiogenesis, and HIV infection. While most CXC chemokines are chemotactic for neutrophils, MIG and INP10 are unusual and similar in being CXC chemokines that are chemotactic for lymphocytes and inactive in neutrophils.
Specifications
CXCL9 | |
Monoclonal | |
FITC | |
CXCL9 | |
BB139920; C Cmotif chemokine; C X C motif chemokine; CC motif chemokine; CCmotif chemokine; chemokine (C-X-C motif) ligand 9; CMK; crg-10; CXC; CXC motif chemokine; C-X-C motif chemokine 9; C-X-C motif chemokine ligand 9; CXCL; CXCL9; gamma interferon-induced monokine; gamma-interferon-induced monokine; HuMIG; M119; Mig; monokine induced by gamma interferon; monokine induced by interferon gamma; monokine induced by interferon-gamma; MuMIG; protein m119; SCYB9; small inducible cytokine B subfamily (Cys-X-Cys), member 9; small inducible cytokine B9; small-inducible cytokine B9 | |
Mouse | |
Protein A/G | |
RUO | |
4283 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
49106 | |
Buffered saline solution with BSA and 0.09% sodium azide | |
Q07325 | |
CXCL9 | |
E. coli-derived recombinant human CXCL9/MIG Thr23-Thr125. | |
100 Tests | |
Primary | |
Human | |
Antibody | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction